NASDAQ:IMACIMAC Stock Price, Forecast & News

IMAC's stock was trading at $0.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMAC stock has increased by 59.8% and is now trading at $1.31.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMAC in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IMAC.

IMAC is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020.
View our earnings forecast for IMAC.

IMAC Holdings Inc (NASDAQ:IMAC) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.18) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01. The firm earned $3.32 million during the quarter, compared to analysts' expectations of $5.72 million. IMAC had a negative net margin of 41.20% and a negative return on equity of 80.08%.
View IMAC's earnings history.

2 brokerages have issued 12 month price targets for IMAC's stock. Their forecasts range from $4.50 to $4.50. On average, they anticipate IMAC's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 243.5% from the stock's current price.
View analysts' price targets for IMAC.

Headlines about IMAC stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. IMAC earned a media sentiment score of -4.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about IMAC.

IMAC saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 152,000 shares, an increase of 65.4% from the June 30th total of 91,900 shares. Based on an average daily trading volume, of 244,200 shares, the days-to-cover ratio is presently 0.6 days. Currently, 2.1% of the company's shares are short sold.
View IMAC's Short Interest.

Some companies that are related to IMAC include Acadia Healthcare (ACHC), BioTelemetry (BEAT), Hanger (HNGR), Biocorrx (BICX) and AAC (AAC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IMAC investors own include NovaBay Pharmaceuticals (NBY), Amarin (AMRN), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Aytu Bioscience (AYTU), Crispr Therapeutics (CRSP), Vaxart (VXRT), Agile Therapeutics (AGRX), Armata Pharmaceuticals (ARMP) and Anavex Life Sciences (AVXL).

(IMAC) raised $4 million in an IPO on the week of February 11th 2019. The company issued 900,000 shares at $5.00 per share. Dawson James Securities and Cuttone served as the underwriters for the IPO.

IMAC trades on the NASDAQ under the ticker symbol "IMAC."

Shares of IMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IMAC stock can currently be purchased for approximately $1.31.

IMAC has a market capitalization of $13.11 million and generates $15.13 million in revenue each year.

The official website for IMAC is www.imacregeneration.com.

IMAC's mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The company can be reached via phone at 844-266-4622 or via email at [email protected]